Author(s)

Zhimin Wu¹, Chunxiao Zhou¹, Chunyan Wu¹, Qiao Song¹, Shilyu Chen¹, Wen Zhang¹, Shaoling Wu^2*

¹Department of Medicine, Qingdao University, Qingdao, China.
²Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Objective: To evaluate the treatment outcome of iron isomaltoside compared with an oral iron supplement in the management of iron deficiency anemia (IDA). Methods: The study included patients with IDA who visited the Outpatient Clinic of the Department of Hematology, the Affiliated Hospital of Qingdao University from October 2021 to August 2022 and met the inclusion and exclusion criteria. According to the actual application of iron supplementation, the patients were divided into two groups: iron isomaltoside treatment group and oral iron treatment group. Baseline measurements were collected before the start of treatment, and measurements were collected subsequently at intervals of 1 week, 1 month, and 3 months. The hematological parameters analyzed included Hemoglobin (Hb), Mean corpuscular hemoglobin (MCH), Mean Hemoglobin content (MCH), Mean corpuscular Hemoglobin concentration (MCHC), and Platelet (Plt). Safety data and adverse event profiles were recorded. Results: Intra-group comparisons: After 1 month of treatment, the Hb significantly improved (P < 0.05). Inter-group comparisons: The biochemical parameters were significantly improved (P < 0.05) in the iron isomaltoside group compared with those in the oral iron group after 1 month of iron supplementation in patients with mild and moderate anemia. Adverse reactions were tolerable for the patients in both iron isomaltoside group and oral iron group. Only 1 patient in iron isomaltoside group developed anaphylactic shock during medication and recovered after aggressive rescue. Conclusions: Iron isomaltoside which increases Hb more rapidly compared with the oral iron supplementation has few adverse reactions and good acceptance.

Anemia, Iron-Deficiency, Drug Therapy, Iron Isomaltoside 1000, Treatment Outcome

Wu, Z. , Zhou, C. , Wu, C. , Song, Q. , Chen, S. , Zhang, W. and Wu, S. (2024) Efficacy and Safety of Iron Isomaltoside Compared with an Oral Iron Supplement in the Management of Patients with Iron Deficiency Anemia. Open Journal of Blood Diseases, 14, 17-30. doi: 10.4236/ojbd.2024.141003.